U.S. stocks closed sharply lower after Federal Reserve Chairman Ben Bernanke said the central bank could reduce its monetary stimulus later this year if the economy continues to improve. read on...
Danaher Corporation's (NYSE: DHR) subsidiary Beckman Coulter, Inc. said the U.S. health regulators approved its new Access AccuTnI+3 troponin I assay for use on its Access 2 immunoassay system. Orange County, California-based Beckman said the assay provides the clinical performance needed for optimal patient management. read on...
Bluebird Bio Inc. (NASDAQ: BLUE), a provider of gene therapy platform, priced its initial public offering (IPO) of 5.94 million shares at $17.00 each, raising $101 million. Shares opened for trading at $25.50 on Wednesday. The company said its most advanced product candidate is called Lenti-D, which it is developing initially to treat patients with CCALD, a rare, hereditary neurological disorder. read on...
Seattle Genetics, Inc. (NASDAQ: SGEN) and Takeda Pharmaceutical Company Limited reported encouraging data from an analysis examining progression-free survival (PFS) following treatment with ADCETRIS. The companies said the data suggest that ADCETRIS may delay disease progression compared to prior therapies in patients diagnosed with relapsed or refractory HL post-autologous stem cell transplant (ASCT) or relapsed or refractory sALCL. read on...
U.S. stocks ended on a positive note as investors awaited monetary policy decision from the Federal Reserve. read on...
Quintiles Transnational Holdings Inc (NYSE: Q) shares were initiated with a "Buy" rating and price target read on...
A number of stocks were upgraded and downgraded by Wall Street analysts on read on...
U.S. stock-index futures pointed to a higher opening on the Wall Street ahead of the Federal Open Market read on...
Insider cluster buys are usually a telltale sign that executive team members and directors believe their read on...